Background: Disturbances in magnesium homeostasis and magnesium supplementation are common in critical illness; however, the association between early intravenous magnesium sulfate administration and clinical outcomes in critically ill patients with pneumonia remains unclear. Methods: This retrospective observational cohort study used data from the Medical Information Mart for Intensive Care IV (version 3.1) database and included critically ill patients admitted to the intensive care unit (ICU) with pneumonia. Patients were classified according to early exposure to intravenous magnesium sulfate, defined as administration from 6 h before to 24 h after ICU admission, or no exposure during this period. The primary outcome was 30-day all-cause mortality, with secondary outcomes including 60-day and 90-day mortality. Associations were evaluated using multivariable Cox proportional hazards models, with prespecified subgroup, interaction, and sensitivity analyses, including propensity score matching. Results: Among 9203 eligible patients, 2975 (32.3%) received early intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment (adjusted hazard ratio [aHR] 0.84; 95% confidence interval [CI] 0.76-0.94; p = .002). Similar associations were observed for 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). Subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007). In a propensity score–matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality (aHR 0.85; 95% CI 0.74-0.96; p = .012). Conclusions: In critically ill patients with pneumonia, early intravenous magnesium sulfate administration was associated with lower mortality. These findings are hypothesis-generating and suggest the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation in this population.
The prognostic value of the modified Nutrition Risk in the Critically Ill (mNUTRIC) score in patients with severe and critical Coronavirus disease 2019 (COVID-19) remains insufficiently defined. This study aimed to assess the predictive performance of the mNUTRIC score for in-hospital mortality in patients with severe and critical COVID-19 admitted to the intensive care unit. We conducted a retrospective cohort study including 355 critically ill patients with severe and critical COVID-19 admitted to a university-affiliated hospital in Vietnam. The mNUTRIC score was calculated using the first available clinical and laboratory values recorded within the first 24 hours of intensive care unit admission. The primary outcome was in-hospital mortality. Associations between the mNUTRIC score and mortality were assessed using multivariable logistic regression. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUC). Overall in-hospital mortality was 36.1%. High nutritional risk, defined as an mNUTRIC score ≥5, was identified in 29.6% of patients. In multivariable analysis, the mNUTRIC score remained independently associated with in-hospital mortality (adjusted odds ratio 1.58, 95% confidence interval 1.24–2.02; P < .001). The mNUTRIC score demonstrated moderate discriminative performance for predicting in-hospital mortality, with an AUC of 0.750 (95% confidence interval 0.698–0.803; P < .001). At the optimal cutoff value of ≥4.5, the sensitivity and specificity for predicting in-hospital mortality were 54.7% and 84.6%, respectively. In critically ill patients with severe and critical COVID-19, the mNUTRIC score was associated with in-hospital mortality and demonstrated moderate prognostic performance. Given the retrospective design, these findings should be interpreted with caution and warrant further prospective validation.